Cell Therapeutics, Inc. (CTIC)
-NasdaqCM 1.22 
0.07(5.43%) 4:00PM EDT|After Hours
:
1.22 0.00 (0.00%) 4:36PM EDT
| Prev Close: | 1.29 |
|---|
| Open: | 1.23 |
|---|
| Bid: | 1.20 x 1500 |
|---|
| Ask: | 1.27 x 10000 |
|---|
| 1y Target Est: | 4.00 |
|---|
| Beta: | 1.5 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 1.20 - 1.24 |
|---|
| 52wk Range: | 1.02 - 4.65 |
|---|
| Volume: | 878,275 |
|---|
| Avg Vol (3m): | 1,037,380 |
|---|
| Market Cap: | 130.17M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.57 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Cell Therapeutics, Inc. Presents at UBS Global Healthcare Conference, May-21-2013 02:30 PMat Seeking Alpha(Tue, May 21)
- German Federal Joint Committee (G-BA) Issues Final Assessment Report for PIXUVRI® (pixantrone)PR Newswire(Mon, May 20)
- Cell Therapeutics to Present at Upcoming Investor ConferencesPR Newswire(Wed, May 15)
- CELL THERAPEUTICS INC FinancialsEDGAR Online Financials(Fri, May 10)
- Cell Therapeutics, Inc. Earnings Call scheduled for 4:30 pm ET todayCCBN(Thu, May 2)
- Cell Therapeutics Reports First Quarter 2013 Financial ResultsPR Newswire(Thu, May 2)
- CELL THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhEDGAR Online(Thu, May 2)
- Q1 2013 Cell Therapeutics, Inc. Earnings Release - After Market CloseCCBN(Thu, May 2)
- In Development-Stage Biotechs, Success Comes Down to One Asset: Expert Analyst Boris Peaker Discusses the Competitive Biotechnology Environment with The Wall Street TranscriptWall Street Transcript(Wed, May 1)
- CELL THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, FiEDGAR Online(Tue, Apr 30)
- Cell Therapeutics to Report First Quarter Financial Results after Market on May 2, 2013PR Newswire(Wed, Apr 24)
- FDA Says, "Call Me Maybe"at Motley Fool(Thu, Apr 18)
- Cell Therapeutics: Addicted to Reverse Stock Splitsat TheStreet(Thu, Apr 18)
- Show of support for Cell TherapeuticsoptionMONSTER(Thu, Apr 11)
- Draft NICE Guidance for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI® (pixantrone)PR Newswire(Wed, Apr 10)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 122.24 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.61 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.17 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Cell Therapeutics, Inc. engages in the acquisition, development, and commercialization of treatments for cancer. The company primary focuses on the commercialization of PIXUVRI, an aza-anthracenedione derivative, which is in Phase III clinical tri...
View More